NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free CYCN Stock Alerts $2.77 -0.28 (-9.18%) (As of 09:38 AM ET) Add Compare Share Share Today's Range$2.77▼$2.7750-Day Range$2.77▼$3.5052-Week Range$1.75▼$6.75Volume670 shsAverage Volume3,210 shsMarket Capitalization$7.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cyclerion Therapeutics alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Cyclerion Therapeutics Stock (NASDAQ:CYCN)Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More CYCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYCN Stock News HeadlinesApril 21, 2024 | morningstar.comCyclerion Therapeutics Inc Ordinary Shares CYCNApril 18, 2024 | americanbankingnews.comCyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 6.0% in MarchApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 5, 2024 | investorplace.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023March 6, 2024 | investing.comCyclerion Therapeutics Inc (CYCN)February 29, 2024 | uk.finance.yahoo.comCyclerion Therapeutics, Inc. (CYCN)February 23, 2024 | benzinga.comCyclerion Therapeutics Stock (NASDAQ:CYCN) Dividends: History, Yield and DatesDecember 4, 2023 | msn.comCyclerion Therapeutics appoints Graul as PresidentApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”November 30, 2023 | finance.yahoo.comCyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge InnovatorNovember 28, 2023 | finance.yahoo.comCyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With LossesJuly 31, 2023 | finance.yahoo.comTisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion AssetsJune 30, 2023 | ca.finance.yahoo.comCYCN - Cyclerion Therapeutics, Inc.June 2, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 1, 2023 | msn.comCyclerion Therapeutics in compliance with Nasdaq minimum bid price ruleMay 16, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Reverse Stock SplitMay 15, 2023 | msn.comCyclerion announces 1 for 20 reverse stock splitMay 12, 2023 | finance.yahoo.comCyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New InvestorsMay 12, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 12, 2023 | msn.comCyclerion Therapeutics down 6% on spin off agreementMay 11, 2023 | finance.yahoo.comCyclerion Announces Corporate Updates and Q1 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comCyclerion Announces Definitive Agreement for Zagociguat and CY3018April 3, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment AgreementMarch 27, 2023 | marketwatch.comCyclerion Gets FDA Orphan Designation for Zagociguat in Mitochondrial Diseases >CYCNMarch 23, 2023 | finanznachrichten.deCyclerion Therapeutics, Inc.: Cyclerion Reports Corporate Update and Full Year 2022 Financial ResultsMarch 22, 2023 | finance.yahoo.comCyclerion Reports Corporate Update and Full Year 2022 Financial ResultsNovember 23, 2022 | msn.comWhy American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From YesterdaySee More Headlines Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYCN CUSIPN/A CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,260,000.00 Net MarginsN/A Pretax Margin-742.76% Return on Equity-111.79% Return on Assets-74.10% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.85 Sales & Book Value Annual Sales$1.62 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.60Miscellaneous Outstanding Shares2,710,000Free Float2,355,000Market Cap$7.51 million OptionableNo Data Beta1.84 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Regina Graul Ph.D.PresidentMs. Rhonda M. Chicko (Age 57)Chief Financial Officer Dr. Todd Milne Ph.D.Senior Vice President of External InnovationMs. Jessica RennekampAssociate Director of Corporate CommunicationsKey CompetitorsVirios TherapeuticsNASDAQ:VIRIMolecular TemplatesNASDAQ:MTEMNuCanaNASDAQ:NCNAHepion PharmaceuticalsNASDAQ:HEPAUniverse PharmaceuticalsNYSE:UPCView All CompetitorsInsiders & InstitutionsTyndall Capital Partners L PBought 16,717 shares on 2/14/2024Ownership: 6.711%Terrance McguireSold 8 sharesTotal: $27.20 ($3.40/share)View All Insider TransactionsView All Institutional Transactions CYCN Stock Analysis - Frequently Asked Questions How have CYCN shares performed in 2024? Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of 2024. Since then, CYCN stock has decreased by 17.3% and is now trading at $2.77. View the best growth stocks for 2024 here. Are investors shorting Cyclerion Therapeutics? Cyclerion Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 22,100 shares, a decline of 6.0% from the March 15th total of 23,500 shares. Based on an average trading volume of 3,000 shares, the days-to-cover ratio is presently 7.4 days. Approximately 1.2% of the company's stock are sold short. View Cyclerion Therapeutics' Short Interest. When is Cyclerion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CYCN earnings forecast. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) issued its earnings results on Tuesday, November, 9th. The company reported ($5.20) EPS for the quarter, beating analysts' consensus estimates of ($7.00) by $1.80. The business earned $0.35 million during the quarter, compared to analysts' expectations of $3 million. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics's stock reverse split on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Biopharma (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX). How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYCN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
